Ribavirin

• 

  Subject Areas on Research

  • A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment. 
  • A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. 
  • Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. 
  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. 
  • Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. 
  • Aerosolized ribavirin: the most expensive drug for pneumonia. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. 
  • Analysis of site performance in academic-based and community-based centers in the IDEAL Study. 
  • Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Boceprevir for HCV in patients with HIV: where next? 
  • Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. 
  • Bronchiolitis. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. 
  • Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. 
  • Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. 
  • Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients. 
  • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 
  • Definition and management of anemia in patients infected with hepatitis C virus. 
  • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. 
  • Diagnosis and treatment of chronic hepatitis C infection. 
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. 
  • Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. 
  • Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. 
  • Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. 
  • Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. 
  • Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. 
  • Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. 
  • Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. 
  • Evidence that ribavirin is transported in Aedes albopictus cells by the nucleoside transport system. 
  • Factors influencing the participation of gastroenterologists and hepatologists in clinical research. 
  • Future trends in managing hepatitis C. 
  • Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. 
  • Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. 
  • Growth factors during HCV therapy may be "cost-effective", but are they "effective"? 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. 
  • Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. 
  • Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. 
  • Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. 
  • Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. 
  • IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. 
  • IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. 
  • ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. 
  • ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. 
  • Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. 
  • In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. 
  • In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 
  • Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 
  • Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. 
  • Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. 
  • Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. 
  • Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. 
  • Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. 
  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. 
  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. 
  • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. 
  • Making it happen: managed care considerations in vanquishing hepatitis C. 
  • Management of hepatitis C virus infection: the basics. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. 
  • New therapies for chronic hepatitis C virus infection. 
  • Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. 
  • PHOTON-2: hope for patients with HIV and HCV co-infection? 
  • Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. 
  • Pericarditis mediated by respiratory syncytial virus in a hematopoietic stem cell transplant patient. 
  • PharmGKB summary: peginterferon-α pathway. 
  • Pharmacologic treatment of bronchiolitis in infants and children: a systematic review. 
  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. 
  • Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Racial differences in hepatitis C treatment eligibility. 
  • Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. 
  • Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. 
  • Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. 
  • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 
  • Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. 
  • Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. 
  • Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper? 
  • Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. 
  • Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. 
  • Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. 
  • Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. 
  • Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. 
  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure. 
  • Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. 
  • Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. 
  • Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. 
  • Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. 
  • Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. 
  • Telaprevir for previously treated chronic HCV infection. 
  • Telaprevir for the treatment of chronic hepatitis C infection. 
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. 
  • The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA. 
  • The rapid evolution of treatment strategies for hepatitis C. 
  • Treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Treatment of hepatitis C in special populations. 
  • Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. 
  • Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. 
  • Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. 
  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.